The National Institutes of Health (NIH) COVID-19 Portal collects data on diagnostic, therapeutic, vaccine, and other candidates or technologies with near-term potential for testing against COVID-19, as well as other information that could be leveraged in the response to COVID-19. The portal will assist in developing a complete inventory of potential candidates and technologies with different approaches to preventing or mitigating infection.
In response to the COVID-19 pandemic, the NIH is launching several initiatives aimed at speeding innovation, development, and commercialization of diagnostics, therapeutics, vaccines, and biomedical technologies, including the Rapid Acceleration of Diagnostics (RADx) initiative and the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership. RADx aims to speed the development and commercialization of diagnostics with the end goal of enabling rapid, accurate, and widely accessible COVID-19 testing. As a key part of this effort, RADx will include a “shark tank”-like national technology development competition that provides support to participants with the most-promising technologies.
The planned Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership is a public-private partnership between NIH and the Foundation for NIH (FNIH). This partnership will develop a collaborative framework for prioritizing vaccine and drug candidates, streamlining clinical trials, coordinating regulatory processes, and/or leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics. Participating organizations include leading biopharmaceutical companies, the Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response, the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), the U.S. Department of Veterans Affairs (VA), the U.S. Department of Defense, and the European Medicines Agency (EMA).
The NIH COVID-19 portal will help address the needs of the various initiatives by cataloging diagnostic, therapeutic, vaccine, and other candidates or technologies. NIH will work closely with the Biomedical Advanced Research and Development Authority (BARDA), CDC, and FDA to coordinate the rapid acceleration of development for promising candidate technologies.
Please fill out the webform below with all required information about the diagnostic, therapeutic, vaccine, or other candidate or technology for awareness of NIH. Stakeholders throughout the biopharmaceutical, academic, scientific research, advocacy, clinical practice communities, and the general public are welcome to submit.
Please note that this portal is for information and planning purposes only and shall not be construed as a solicitation or funding opportunity; as a contract, grant, cooperative agreement, or other transaction; or as an obligation on the part of the Federal Government, the NIH, or individual NIH Institutes and Centers to provide support for any ideas identified in response to it. All portions of the submission that are proprietary, confidential, or trade secret should be clearly marked as such.
Following submission, should additional information be desired, a representative of NIH may be in contact. Your input is a valuable component in developing a response to the COVID-19 pandemic, and your time and consideration are appreciated.
For more information: https://grants.nih.gov/grants/rfi/rfi.cfm?ID=107